M. Keane (Dublin 4, Ireland), D. Israel-Biet (Paris, France), C. Ravaglia (Brisighella, Italy), F. Bonella (Dusseldorf, Germany)
Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017 S. Homma (Tokyo, Japan)
| |
Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone K. Ikeda (Sapporo, Japan)
| |
The effect of mechanical ventilation to acute exacerbation of IPF and CTD-ILD Y. Ma (Beijing, China)
| |
Effect of nintedanib on multidimensional evaluation in patients with IPF K. Kataoka (Seto, Aichi, Japan)
| |
Bronchoalveolar lavage in idiopathic pulmonary fibrosis S. Aouadi (Ariana, Tunisia)
| |
Our transbronchial lung cryobiopsy experience in 29 patient with ILDs A. Çirak (Izmir, Turkey)
| |
Quality of life of idiopathic pulmonary fibrosis patients E. Barczi (Budapest, Hungary)
| |
Impact of specific organic exposure on the prognosis in Idiopathic Pulmonary Fibrosis L. De Sadeleer (LEUVEN, Belgium)
| |
Safety, feasibility and diagnostic yield of bronchoscopic lung cryobiopsy in diffuse parenchymal lung disease- retrospective review of 100 procedures.> A. O'Mahony (Co. Cork, Ireland)
| |
A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients A. Caminati (Milano, MI, Italy)
| |
Mortality in biopsy verified usual interstitial pneumonia and the relation to computed tomography scores V. Søyseth (Oslo, Norway)
| |
Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience A. Fui (La Spezia, SP, Italy)
| |
Plasma fibronectin as the criterion of idiopathic fibrosing alveolitis severity O. Karasyova (Dnepr, Ukraine)
| |
Expression of mRNA of selected inflammatory markers in BALf cells from patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF) M. Maskey-Warzechowska (Warszawa, Poland)
| |
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? V. Müller (Budapest, Hungary)
| |
Assessment of general physicians’ knowledge in the public and private sectors about interstitial lung disease. S. Kulkarni (Aurangabad (Maharashtra), India)
| |
Diffuse alveolar hemorrhage: how relevant is etiology? A. Terras Alexandre (Bragança, Portugal)
| |
Global characterisation of routine care interstitial lung disease diagnostic practice L. Richeldi (Southampton, United Kingdom)
| |
Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study. L. Tavanti (Pisa, Italy)
| |